Cogent Biosciences (COGT) Common Equity (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Common Equity of $607.7 million for Q1 2026, up 177.49% year-over-year from $219.0 million in Q1 2025, and down 4.51% quarter-over-quarter from $636.4 million in Q4 2025.
Cogent Biosciences (COGT) Common Equity (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Common Equity for 10 consecutive years, with $607.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 177.49% year-over-year to $607.7 million; the TTM figure through Mar 2026 stood at $607.7 million (up 177.49% YoY), while the FY2025 annual figure was $636.4 million, up 148.31% from the prior year.
- Common Equity eased to $607.7 million in Q1 2026 per COGT's latest filing, from $636.4 million in the prior quarter.
- Across five years, Common Equity topped out at $636.4 million in Q4 2025 and bottomed at $155.0 million in Q2 2025.
- Historically, Common Equity has averaged $321.9 million across 5 years, with a median of $302.5 million in 2025.
- Annual changes were most pronounced in 2025 — Common Equity tumbled 58.46% — and 2026, when it surged 177.49%.
- Cogent Biosciences' Common Equity stood at $255.7 million in 2022, then advanced by 0.81% to $257.8 million in 2023, then slipped by 0.59% to $256.3 million in 2024, then surged by 148.31% to $636.4 million in 2025, then slipped by 4.51% to $607.7 million in 2026.
- Business Quant data shows COGT's Common Equity at $607.7 million in Q1 2026, $636.4 million in Q4 2025, and $302.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | 532.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 532.39 Mn |
| Mar 31, 2026 | 607.69 Mn |
| Dec 31, 2025 | 636.37 Mn |
| Sep 30, 2025 | 302.46 Mn |
| Jun 30, 2025 | 155.04 Mn |
| Mar 31, 2025 | 219.00 Mn |
| Dec 31, 2024 | 256.29 Mn |
| Sep 30, 2024 | 314.66 Mn |
| Jun 30, 2024 | 373.22 Mn |
| Mar 31, 2024 | 422.33 Mn |
| Dec 31, 2023 | 257.80 Mn |
| Sep 30, 2023 | 302.90 Mn |
| Jun 30, 2023 | 348.43 Mn |
| Mar 31, 2023 | 223.56 Mn |
| Dec 31, 2022 | 255.74 Mn |
| Sep 30, 2022 | 289.94 Mn |
| Jun 30, 2022 | 319.39 Mn |
| Mar 31, 2022 | 187.86 Mn |
| Dec 31, 2021 | 214.18 Mn |
| Sep 30, 2021 | 197.24 Mn |